Belvedere Trading
CRDL

Belvedere Trading’s Cardiol Therapeutics CRDL Stock Holding History

Belvedere Trading’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-80,200
Closed -$146K – 399
2022
Q1 		$146K Buy
80,200
+100
+0.1% +$165 ﹤0.01% 274
2021
Q4 		$146K Buy
+80,100
New +$221K 0.01% 250

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHIC
Marble Harbor Investment Counsel Boston, Massachusetts $923M AUM 14.09% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Belvedere Trading's CRDL Position: Q2 2022 in Review

Belvedere Trading sold out of Cardiol Therapeutics (CRDL) in Q2 2022, closing a stake of 16,010 shares — an estimated $29K sold.

Belvedere Trading first reported a position in CRDL in Q4 2021 and held it in 2 quarters. The position peaked at $49K in Q4 2021. 27 funds tracked by Wall St. Rank hold CRDL as of Q2 2022.

  • Belvedere Trading reported no remaining Cardiol Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Belvedere Trading sold 16,010 Cardiol Therapeutics shares in Q2 2022, an estimated $29K.
  • Belvedere Trading first reported a position in Cardiol Therapeutics in Q4 2021 and held it in 2 quarters.
  • Belvedere Trading's Cardiol Therapeutics position peaked at $49K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2022.

Based on Belvedere Trading's 13F filing for Q2 2022, filed 21 Jul 2022.